Yoshitaka Sekine

Yoshitaka Sekine

Auto-generated profile, based on publicly available information

Yoshitaka Sekine

Department of Urology Gunma University Graduate School of Medicine Maebashi Japan

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2002 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
KSKazuhiro Suzuki
Kazuhiro Suzuki
HKHidekazu Koike
Hidekazu Koike
HMHiroshi Matsui
Hiroshi Matsui
YOYoshihiro Ono
Yoshihiro Ono
MHMasaru Hasumi
Masaru Hasumi
HYHidetoshi Yamanaka
Hidetoshi Yamanaka
Genistein is a major component of soybean isoflavone and has multiple functions resulting in antitumor effects. Prostate cancer is 1 of the targets for the preventive role of genistein. We examined the effect of genistein on human prostate cancer (LNCaP and PC‐3) cells. Proliferation of both cell lines was inhibited by genistein treatment in a dose‐dependent manner. To obtain the gene expression profile of genistein in LNCaP cells, we performed cDNA microarray analysis. The expression of many genes, including apoptosis inhibitor (survivin), DNA topoisomerase II, cell division cycle 6 (CDC6) and mitogen‐activated protein kinase 6 (MAPK 6), was downregulated. Expression levels were increased more than 2‐fold in only 4 genes. The glutathione peroxidase (GPx)‐1 gene expression level was the most upregulated. Quantitative real‐time polymerase chain reaction revealed significant elevation of transcript levels of GPx‐1 in both LNCaP and PC‐3 cells. Upregulation of gene expression levels accompanied elevation of GPx enzyme activities. In contrast, no significant changes were observed in the gene expression levels and enzyme activities of the other antioxidant enzymes, superoxide dismutase and catalase. GPx activation might be one of the important characteristics of the effects of genistein on prostate cancer cells.

1 September 2010 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
YSYoshitaka Sekine
Yoshitaka Sekine
SDSteve J. Demosky
Steve J. Demosky
JSJohn A. Stonik
John A. Stonik
YFYosuke Furuya
Yosuke Furuya
HKHidekazu Koike
Hidekazu Koike
ARAlan T. Remaley
Alan T. Remaley
Androgen deprivation therapy for prostate cancer leads to a significant increase of high-density lipoprotein (HDL), which is generally viewed as beneficial, particularly for cardiovascular disease, but the effect of HDL on prostate cancer is unknown. In this study, we investigated the effect of HDL on prostate cancer cell proliferation, migration, intracellular cholesterol levels, and the role of cholesterol transporters, namely ABCA1, ABCG1, and SR-BI in these processes. HDL induced cell proliferation and migration of the androgen-independent PC-3 and DU145 cells by a mechanism involving extracellular signal-regulated kinase (ERK) 1/2 and Akt, but had no effect on the androgen-dependent LNCaP cell, which did not express ABCA1 unlike the other cell lines. Treatment with HDL did not significantly alter the cholesterol content of the cell lines. Knockdown of ABCA1 but not ABCG1 or SR-BI by small interfering RNA (siRNA) inhibited HDL-induced cell proliferation, migration, and ERK1/2 and Akt signal transduction in PC-3 cells. Moreover, after treatment of LNCaP cells with charcoal-stripped fetal bovine serum, ABCA1 was induced ∼10-fold, enabling HDL to induce ERK1/2 activation, whereas small interfering RNA knockdown of ABCA1 inhibited HDL-induced ERK1/2 activation. Simvastatin, which inhibited ABCA1 expression in PC-3 and DU145 cells, attenuated HDL-induced PC-3 and DU145 cell proliferation, migration, and ERK1/2 and Akt phosphorylation. In human prostate biopsy samples, ABCA1 mRNA expression was ∼2-fold higher in the androgen deprivation therapy group than in subjects with benign prostatic hyperplasia or pretreatment prostate cancer groups. In summary, these results suggest that HDL by an ABCA1-dependent mechanism can mediate signal transduction, leading to increased proliferation and migration of prostate cancer cells. Mol Cancer Res; 8(9); 1284–94. ©2010 AACR.

1 May 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HKHaruo Kato
Haruo Kato
YSYoshitaka Sekine
Yoshitaka Sekine
YFYosuke Furuya
Yosuke Furuya
YMYoshiyuki Miyazawa
Yoshiyuki Miyazawa
HKHidekazu Koike
Hidekazu Koike
KSKazuhiro Suzuki
Kazuhiro Suzuki

10 June 2019 in International Journal of Urology
Verified
Journal Article
Open access
PDF file
KIKAZUTO ITO
KAZUTO ITO
RORyo Oki
Ryo Oki
YSYoshitaka Sekine
Yoshitaka Sekine
SASeiji Arai
Seiji Arai
YMYoshiyuki Miyazawa
Yoshiyuki Miyazawa
IKIsao Kurosawa
Isao Kurosawa
Differences in the incidence and mortality rate of prostate cancer between the USA and Japan have been decreasing over time, and were only twofold in 2017. Therefore, countermeasures against prostate cancer could be very important not only in Western countries, but also in developed Asian countries. Screening for prostate cancer in the general population using transrectal ultrasonography, digital rectal examination and/or prostate acid phosphatase began in Japan in the early 1980s, and screening with prostate‐specific antigen and digital rectal examination has been widespread in the USA since the late 1980s. Large‐ and mid‐scale randomized controlled trials on screening for prostate cancer began around 1990 in the USA, Canada and Europe. However, most of these studies failed as randomized controlled trials because of high contamination in the control arm, low compliance in the screening arm or insufficient screening setting about screening frequency and/or biopsy indication. The best available level 1 evidence is data from the European Randomized Study of Screening for Prostate Cancer and the Göteborg screening study. However, several non‐urological organizations and lay media around the world have mischaracterized the efficacy of prostate‐specific antigen screening. To avoid long‐term confusion about screening for prostate cancer, leading professional urological organizations, including the Japanese Urological Association, are moving toward the establishment of an optimal screening system that minimizes the drawbacks of overdetection, overtreatment and loss of quality of life due to treatment, and maximizes reductions in the risk of death as a result of prostate cancer and the development of metastatic prostate cancer.

1 June 2016 in Prostate International
Verified
Journal Article
Open access
YFYosuke Furuya
Yosuke Furuya
YSYoshitaka Sekine
Yoshitaka Sekine
HKHaruo Kato
Haruo Kato
YMYoshiyuki Miyazawa
Yoshiyuki Miyazawa
HKHidekazu Koike
Hidekazu Koike
KSKazuhiro Suzuki
Kazuhiro Suzuki
There are some reports about the antitumor effects of statins in these days. Statins decrease the level of cholesterol in the blood by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Inhibition of this enzyme decreases intracellular cholesterol synthesis. Thus, the expression of low-density lipoprotein receptor (LDLr) is increased to import more cholesterol from the bloodstream. In this study, we assessed the effects of statins on the proliferation of prostate cancer cells, and studied the relationship between the expression of LDLr and the effects of statins. Simvastatin was used in the experiments. We studied the effect of simvastatin on PC-3 and LNCaP cell proliferation using the MTS assay, and evaluated the expression of LDLr after administration of simvastatin by quantitative polymerase chain reaction and Western blotting. Intracellular cholesterol levels in the prostate cancer cells were measured after administration of simvastatin. Furthermore, small interfering RNA (siRNA) was used to knockdown the gene expression of LDLr. In PC-3 cells, simvastatin inhibited cell proliferation. In LNCaP cells, only a high concentration of simvastatin (100μM) inhibited cell proliferation. In LNCaP cells, the protein level of LDLr was increased by simvastatin. In PC-3 cells, the protein levels of LDLr were unregulated. In PC-3 cells, but not in LNCaP cells, intracellular cholesterol levels were significantly decreased by simvastatin. After knocking down LDLr expression by siRNA, intracellular cholesterol levels were decreased, and cell proliferation was inhibited by simvastatin in LNCaP cells. Simvastatin inhibited prostate cancer cell growth by decreasing cellular cholesterol and could be more effective in androgen-independent prostate cancer, where there is loss of regulation of LDLr expression. LDLr was shown to play an important role in the statin-induced inhibition of prostate cancer cell proliferation. These results suggest that future studies evaluating the cholesterol-lowering effects of statin may lead to new approaches to the prevention and treatment of prostate cancer.

18 August 2012 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
KIKazuto Ito
Kazuto Ito
MMMai Miyakubo
Mai Miyakubo
YSYoshitaka Sekine
Yoshitaka Sekine
HKHidekazu Koike
Hidekazu Koike
HMHiroshi Matsui
Hiroshi Matsui
KSKazuhiro Suzuki
Kazuhiro Suzuki